A Russian asbestos company is now flippantly marketing its products with the face of President Donald Trump and his alleged approval. The Mesothelioma Applied Research Foundation knows that the patients and community we work with every day are the true faces of mesothelioma, a deadly cancer expected to kill more than 100,000 Americans over the […]
Articles by Meso Foundation
One of this year’s American Society for Clinical Oncology (ASCO) updates in mesothelioma included the release of the first results for the Phase 2 Study of the EZH2 inhibitor, tazemetostat, for malignant mesothelioma, presented by the chair of the board of the Mesothelioma Applied Research Foundation (Meso Foundation), Marjorie Zauderer, MD.
This study enrolled 61 BAP1 […]
Earlier this month, during the most recent meeting of the American Society of Clinical Oncology (ASCO), first results from a new study are bound to bring hope to the mesothelioma community.
The aptly named DREAM study coming out of Australia is one of the first of its kind in mesothelioma, and so far, its results look […]
The Mesothelioma Applied Research Foundation (Meso Foundation) announced this week that Marjorie Zauderer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, has been voted chair of the board of directors, which governs the organization. She first joined the board in 2017.
Dr. Zauderer succeeded the previous chair Dr. Richard Alexander, a surgeon at Rutgers […]
On Friday morning, we made our first stop on the 2018 International Symposium on Malignant Mesothelioma tour in Minneapolis, MN! Our executive director Mary Hesdoffer, NP and Science Advisory Board chair Dr. Tobias Peikert welcomed attendees to the one-day conference followed by an overview of our work in research, education, support and advocacy by director of […]